



Kyowa Hakko Kogyo Co., Ltd.

Consolidated Financial Summary

Fiscal 2006 Third Quarter

(April 1, 2006 – December 31, 2006)

This document is an English translation of parts of the Japanese-language original. All financial information has been prepared in accordance with generally accepted accounting principles in Japan. It contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. Actual financial results may differ materially depending on a number of factors, including fluctuations in exchange rates, changing economic conditions, legislative and regulatory developments, delays in new product launches, and pricing and product initiatives of competitors.



Third Quarter Performance Update For The Year Ending March 31, 2007

Kyowa Hakko Kogyo Co., Ltd.

January 29, 2007

| | | |
|------------------------------------|---|--|
| Stock Code: 4151 | Listed Exchanges: 1 st Section of the Tokyo Stock Exchange | |
| Telephone: +81 3 3282 0009 | President: Yuzuru Matsuda | |
| URL: www.kyowa.co.jp/eng/index.htm | Inquiries: Tetsuro Kuga | |
| | | General Manager, Corporate Communications Department |

1. Notes relating to the preparation etc., of quarterly business performance updates

- a) Simplified accounting treatments were adopted
No adjustments for cost variance were applied
- b) There were no changes to accounting treatments from the previous fiscal year.
- c) There was one change to the scope of consolidation and one change to equity method accounting
Details of changes:
Shanghai Kyowa Amino Acid Co., Ltd. was newly included in the scope of consolidation
Musashino Chemical Laboratory, Ltd. was excluded from the scope of equity method accounting

2. Results for the nine months ended December 31, 2006

- (1) Progress of consolidated business performance

Amounts less than 1 million yen have been ignored

Millions of yen

| | Nine months to December 31, 2006 | Change (%) | Nine months to December 31, 2005 | Change (%) | FY ended March 31, 2006 |
|--|--|---------------|--|---------------|-------------------------------|
| Net sales | 268,113 | (1.5) | 272,258 | (1.0) | 353,439 |
| Operating income | 26,873 | 17.5 | 22,878 | (12.3) | 25,534 |
| Recurring income | 27,597 | 6.2 | 25,983 | (0.4) | 28,219 |
| Net income | 11,671 | (20.4) | 14,661 | (4.2) | 16,273 |
| Net income per share (¥) | ¥28.63 | -- | ¥34.67 | -- | ¥38.36 |
| Fully diluted net income per share (¥) | ¥28.61 | -- | ¥34.66 | -- | ¥38.35 |

Notes: Percentages for net sales, and operating income, etc., show changes compared to the comparable period of the previous fiscal year.



Summary of business performance

For the nine-month period ended December 31, 2006, net sales were ¥268.1 billion, down ¥4.1 billion, or 1.5% compared to the first nine-months of the previous fiscal year. Results were however ahead of initial plans for the fiscal year, driven mainly by strong performances from the Pharmaceuticals business and the Chemicals business.

In the Pharmaceuticals business, despite pharmaceutical price cuts introduced in April 2006, core pharmaceutical products overall delivered a strong performance. Higher sales volumes of *Allelock* (*olopatadine hydrochloride*), an antiallergic agent, resulted in sales similar to those in the first nine months of the previous fiscal year, and *Durotep Patch*, an analgesic for persistent cancer pain, recorded an increase in sales. *Coniel*, a treatment for hypertension and angina pectoris, maintained sales volumes, despite competition from generic products launched in July 2006, and *Patanol*, an ophthalmic solution, which was launched in October 2006, rapidly penetrated its market and contributed to sales. However, net sales in the Pharmaceuticals business were lower than in the first nine months of the previous fiscal year, affected by a large fall in sales of antimycological agent *Itrizole* after the ending of its distribution agreement in March 2006 (sales in the first nine months of last fiscal year: ¥19.4 billion).

In the Bio-Chemicals business, sales increased compared to the first nine months of last fiscal year. Despite continued intense price competition in domestic and overseas markets, core amino acid, nucleic acid and related compounds performed well, and generic pharmaceutical raw materials, mail-order sales of the *Remake* series, and industrial-use alcohol, each increased sales.

In the Chemicals business, market prices of products generally maintained high levels in Japan and overseas, and sales increased significantly.

In the Food business, continued growth in *umami* seasonings contributed to higher sales.

The strong performance from core pharmaceutical products, along with a decrease in R&D expenses and personnel costs, resulted in operating income for the nine-month period of ¥26.8 billion, an increase of ¥3.9 billion, or 17.5%. Recurring income increased by 6.2% to ¥27.5 billion, while net income for the period was affected by extraordinary losses, including losses from the sale of equity in related companies, as well as asset impairment losses, and declined by 20.4% to ¥11.6 billion.

(2) Changes in consolidated financial position

Millions of yen

| | As of December 31, 2006 | As of December 31, 2005 | As of March 31, 2006 |
|--------------------------------|----------------------------|----------------------------|-------------------------|
| Total assets | 374,582 | 390,945 | 384,381 |
| Net assets | 243,153 | 251,587 | 255,807 |
| Shareholders' equity ratio (%) | 64.3% | 64.4% | 66.6% |
| Net assets per share (¥) | ¥605.02 | ¥595.03 | ¥604.92 |



Consolidated cash flows

Millions of yen

| | April 1, 2006 to December 31, 2006 | April 1, 2005 to December 31, 2005 | April 1, 2005 to March 31, 2006 |
|--|--|--|---------------------------------------|
| Cash flows from operating activities | 16,265 | 6,581 | 14,303 |
| Cash flows from investing activities | (4,821) | 963 | (1,795) |
| Cash flows from financing activities | (24,109) | (5,052) | (5,139) |
| Cash and cash equivalents at end of period | 33,364 | 40,732 | 45,820 |

Summary of financial position

Total assets as of December 31, 2006 were ¥374.5 billion, a decrease of ¥9.7 billion from the end of March 2006. Current assets declined by ¥1.2 billion from the end of March 2006, as despite an increase in accounts and notes receivable, cash and time deposits, and marketable securities declined due to the purchase in July 2006 of treasury stock at a total cost of ¥20.4 billion. Fixed assets declined ¥8.5 billion from the end of March 2006 as investment securities declined as a result of the sale of equity in affiliates and a decline in the market price of listed equity holdings.

Liabilities increased by ¥4.5 billion from the end of March 2006 to ¥131.4 billion at the end of December 2006 as a decrease in the reserves for bonuses and retirement benefit allowances was offset by an increase in account and notes payable.

Net assets were ¥243.1 billion, as despite net income for the period of ¥11.6 billion, there was a significant expenditure for the acquisition of treasury stock. As a result the equity ratio at the end of December 2006 was 64.3%, a decline of 2.3 percentage points compared to the end of March 2006.

Cash flow from operating activities was ¥16.2 billion, an increase of ¥9.6 billion compared to the nine month period ended December 31, 2005. The main causes were a decrease in the reserve for retirement benefit allowances, and a decrease in the amount of income tax paid.

Cash used in investing activities was ¥4.8 billion, an increase of ¥5.7 billion over the ¥0.9 billion inflow recorded in the nine months to December 31, 2005 as proceeds of ¥3.9 billion from the sale of investment securities were offset by payment of ¥9.0 billion for the acquisition of tangible fixed assets.

Cash flow used in financing activities was ¥24.1 billion, an increase of ¥19.0 billion compared to the nine months to December 31, 2005. The main reason was a ¥20.4 billion increase in payments for the procurement of treasury stock.

As a result, cash and cash equivalents at the end of December 2006 were ¥33.3 billion, a decline of ¥12.4 billion compared to the end of March 2006.



3. Forecasts for the fiscal year ending March 31, 2007

| | <i>Millions of yen</i> |
|------------------|---------------------------------|
| | April 1, 2006 to March 31, 2007 |
| Net sales | 353,000 |
| Operating income | 29,000 |
| Recurring income | 29,000 |
| Net Income | 12,000 |

Forecast net income per share (full year): ¥30.14

Summary of forecasts

Our results for the first nine months of fiscal 2006 were ahead of plan, driven in particular by strong performances from the Pharmaceuticals and Chemicals businesses. However, no change has been made to our fiscal year forecasts that were announced with our interim results on October 30, 2006, as we have announced a joint development and sales contract for inflammatory bowel disease agent *Asaco* with Zeria Pharmaceutical Co., Ltd., which is expected to result in an increase in R&D expenses resulting from initial contract payments.

*The above forecasts are based on information available and assumptions made about a number of uncertain factors at the time of release of this document that can affect results in the future. It is possible that actual results are materially different for a wide variety of reasons.



1. Consolidated balance sheets

Millions of yen

| | As of December 31, 2006 | As of December 31, 2005 | Change | | As of March 31, 2006 |
|---|-------------------------------|-------------------------------|-----------------|--------------|----------------------------|
| | | | (%) | | |
| ASSETS | | | | | |
| Current assets: | | | | | |
| Cash and time deposits | 19,601 | 24,360 | | | 26,019 |
| Accounts and notes receivable | 112,820 | 115,078 | | | 97,828 |
| Marketable securities..... | 12,993 | 11,999 | | | 15,494 |
| Inventories..... | 54,575 | 53,812 | | | 55,485 |
| Deferred tax assets..... | 3,595 | 5,301 | | | 6,365 |
| Other current assets | 8,434 | 13,088 | | | 11,981 |
| (Less) Allowance for doubtful accounts... | (286) | (196) | | | (189) |
| Total current assets..... | 211,735 | 223,444 | (11,708) | (5.2) | 212,985 |
| Fixed assets: | | | | | |
| Tangible fixed assets: | | | | | |
| Buildings and structures..... | 35,751 | 37,894 | | | 37,222 |
| Machinery and equipment | 23,989 | 22,541 | | | 22,403 |
| Land..... | 20,261 | 20,159 | | | 20,268 |
| Construction in progress | 4,397 | 1,760 | | | 2,782 |
| Other..... | 5,307 | 5,372 | | | 5,511 |
| Total tangible fixed assets..... | 89,708 | 87,728 | 1,979 | 2.3 | 88,188 |
| Intangible fixed assets | 657 | 180 | 476 | 263.1 | 402 |
| Investments and other assets: | | | | | |
| Investments in securities..... | 63,053 | 68,359 | | | 72,244 |
| Long-term loans | 2,555 | 2,602 | | | 2,534 |
| Deferred tax assets..... | 366 | 475 | | | 343 |
| Other investments and other assets..... | 8,199 | 9,701 | | | 9,293 |
| Allowance for doubtful accounts..... | (1,244) | (1,078) | | | (1,160) |
| Allowance for investment valuations..... | (448) | (469) | | | (449) |
| Total investments and other assets..... | 72,481 | 79,591 | (7,109) | (8.9) | 82,804 |
| Total fixed assets..... | 162,847 | 167,501 | (4,653) | (2.8) | 171,396 |
| Total assets..... | 374,582 | 390,945 | (16,362) | (4.2) | 384,381 |



Millions of yen

| | As of December 31, 2006 | As of December 31 2005 | Change | | As of March 31, 2006 |
|--|-------------------------------|------------------------------|----------------|--------------|----------------------------|
| | | | | (%) | |
| LIABILITIES: | | | | | |
| Current liabilities: | | | | | |
| Accounts and notes payable | 56,321 | 59,563 | | | 46,869 |
| Short-term bank loans..... | 13,286 | 12,205 | | | 12,203 |
| Accrued expenses | 16,558 | 15,938 | | | 16,100 |
| Income taxes payable | 3,510 | 3,017 | | | 3,828 |
| Reserve for sales rebates | 1,138 | 1,318 | | | 1,072 |
| Reserve for sales returns | 43 | 44 | | | 38 |
| Reserve for sales promotion expenses..... | 890 | 867 | | | 718 |
| Reserve for bonuses | 4 | -- | | | 3,303 |
| Reserve for fixed asset disposal..... | -- | 1,107 | | | -- |
| Other current liabilities | 10,460 | 10,437 | | | 10,013 |
| Total current liabilities..... | 102,213 | 104,501 | (2,287) | (2.2) | 94,148 |
| Long-term liabilities: | | | | | |
| Long-term debt | 12 | 14 | | | 12 |
| Deferred tax liabilities..... | 6,546 | 6,473 | | | 7,382 |
| Retirement benefit allowance..... | 21,789 | 25,975 | | | 24,516 |
| Directors' retirement benefit allowance..... | 98 | 83 | | | 92 |
| Other long-term liabilities..... | 768 | 670 | | | 738 |
| Total long-term liabilities..... | 29,215 | 33,217 | (4,001) | (12.0) | 32,742 |
| TOTAL LIABILITIES..... | 131,429 | 137,718 | (6,289) | (4.6) | 126,890 |



| | <i>Millions of yen</i> | | | |
|---|-------------------------------|-------------------------------|--------|-------------------------|
| | As of December 31, 2006 | As of December 31, 2005 | Change | As of March 31, 2006 |
| | | | (%) | |
| Minority interests: | | | | |
| Minority interests | -- | 1,639 | -- | 1,683 |
| SHAREHOLDERS' EQUITY: | | | | |
| Common stock | -- | 26,745 | -- | 26,745 |
| Capital surplus | -- | 43,185 | -- | 43,186 |
| Retained earnings | -- | 169,106 | -- | 170,718 |
| Valuation difference on other marketable securities | -- | 21,941 | -- | 24,338 |
| Foreign exchange adjustment account | -- | (1,390) | -- | (1,152) |
| Treasury stock | -- | (8,000) | -- | (8,028) |
| Total shareholders' equity | -- | 251,587 | -- | 255,807 |
| Total Liabilities, Minority Interests and Shareholders' Equity | -- | 390,945 | -- | 384,381 |
| NET ASSETS: | | | | |
| Shareholders' Equity: | | | | |
| Common stock | 26,745 | -- | -- | -- |
| Capital surplus | 43,180 | -- | -- | -- |
| Retained earnings | 178,212 | -- | -- | -- |
| Treasury stock | (28,639) | -- | -- | -- |
| Total shareholders' equity | 219,498 | -- | -- | -- |
| Valuation and translation adjustments: | | | | |
| Valuation difference on other marketable securities | 22,013 | -- | -- | -- |
| Deferred gains on hedges | 1 | -- | -- | -- |
| Foreign exchange adjustment account | (729) | -- | -- | -- |
| Total valuation and translation adjustment | 21,285 | -- | -- | -- |
| Subscription rights to shares | 45 | -- | -- | -- |
| Minority interests | 2,323 | -- | -- | -- |
| Total net assets | 243,153 | -- | -- | -- |
| Total liabilities and net assets | 374,582 | -- | -- | -- |

Note: Under the previously employed accounting standards the figure for total shareholders' equity as of December 31, 2006 would be ¥240,782 million.



2. Consolidated statements of income

| | <i>Millions of yen</i> | | | | |
|---|--|--|----------------|----------------------|----------------------|
| | April 1, 2006 to December 31, 2006 | April 1, 2005 to December 31, 2005 | Change | (Reference) | (Reference) |
| | | | (%) | to March 31, 2006 | to March 31, 2006 |
| Net sales | 268,113 | 272,258 | (4,144) | (1.5) | 353,439 |
| Cost of sales | 169,190 | 174,013 | (4,822) | (2.8) | 226,472 |
| Gross profit | 98,922 | 98,244 | | | 126,967 |
| Reversal of reserve for sales returns | 38 | 54 | | | 54 |
| Addition to reserve for sales returns | 43 | 44 | | | 38 |
| Adjusted gross profit | 98,918 | 98,254 | 664 | 0.7 | 126,982 |
| Selling, general and administrative expenses | 72,045 | 75,375 | (3,330) | (4.4) | 101,448 |
| Operating income | 26,873 | 22,878 | 3,994 | 17.5 | 25,534 |
| Other income | 2,842 | 5,220 | (2,377) | (45.5) | 6,254 |
| Interest and dividend income | 1,055 | 851 | | | 994 |
| Income from equity method investments | 540 | 545 | | | 679 |
| Others | 1,246 | 3,824 | | | 4,580 |
| Other expenses | 2,118 | 2,115 | 2 | 0.1 | 3,569 |
| Interest expenses | 170 | 141 | | | 186 |
| Others | 1,948 | 1,974 | | | 3,383 |
| Recurring income | 27,597 | 25,983 | 1,614 | 6.2 | 28,219 |
| Extraordinary income | 744 | 1,674 | (929) | (55.5) | 2,352 |
| Gain on sales of fixed assets | 643 | 1,629 | | | 1,655 |
| Gain on sale of affiliates shares | 54 | -- | | | -- |
| Realized profit on sale of investment securities | 32 | 41 | | | 96 |
| Reversal of allowance for doubtful accounts | 14 | 3 | | | 13 |
| Reversal of reserve for expenses on disposal of fixed assets | -- | -- | | | 587 |
| Extraordinary losses | 6,425 | 3,569 | 2,855 | 80.0 | 5,700 |
| Losses related to disposal of affiliates shares | 2,626 | -- | | | -- |
| Asset impairment losses | 2,405 | 738 | | | 1,060 |
| Payment for water used in production | 777 | -- | | | -- |
| Expenses on support for employees' early retirement | 350 | 2,831 | | | 4,639 |
| Losses on restructuring at affiliates | 266 | -- | | | -- |
| Income before income taxes | 21,917 | 24,088 | (2,170) | (9.0) | 24,871 |
| Corporate, local, and enterprise taxes | 6,872 | 6,015 | 857 | 14.3 | 6,887 |
| Corporate tax adjustment | 3,371 | 3,318 | 52 | 1.6 | 1,602 |
| Minority interests in consolidated subsidiaries | 2 | 93 | (91) | (97.7) | 108 |
| Net income | 11,671 | 14,661 | (2,989) | (20.4) | 16,273 |



3. Consolidated Statements of Cash Flows

| | <i>Millions of Yen</i> | | |
|--|--|--|---|
| | April 1, 2006 to December 31, 2006 | April 1, 2005 to December 31, 2005 | (Reference) April 1, 2005 to March 31, 2006 |
| Cash flows from operating activities: | | | |
| Income before income taxes | 21,917 | 24,088 | 24,871 |
| Depreciation and amortization..... | 7,300 | 7,118 | 9,788 |
| Asset impairment losses | 2,405 | 738 | 1,060 |
| Decrease in retirement benefit allowance | (2,732) | (4,593) | (6,053) |
| (Decrease) increase in reserve for bonus payments..... | (3,298) | -- | 3,303 |
| Decrease (increase) in trade receivables..... | (14,655) | (8,824) | 8,665 |
| Decrease (increase) in inventories..... | 1,724 | (3,223) | (4,641) |
| (Decrease) increase in trade payables..... | 8,919 | 9,837 | (3,176) |
| Corporate etc. tax payments | (7,071) | (11,523) | (11,296) |
| Others | 1,756 | (7,036) | (8,219) |
| Net cash provided by operating activities..... | 16,265 | 6,581 | 14,303 |
| Cash flows from investing activities: | | | |
| Payments for purchase of property, plant & equipment..... | (9,034) | (5,487) | (9,001) |
| Proceeds from sale of property, plant & equipment | 787 | 3,149 | 3,215 |
| Proceeds from sale of investment securities | 3,938 | 4,023 | 4,117 |
| Others | (512) | (721) | (127) |
| Net cash (used in) provided by investing activities | (4,821) | 963 | (1,795) |
| Cash flows from financing activities: | | | |
| Payments for purchase of treasury stock | (20,658) | (185) | (233) |
| Dividends paid..... | (4,063) | (4,718) | (4,755) |
| Others | 612 | (148) | (150) |
| Net cash used in financing activities..... | (24,109) | (5,052) | (5,139) |
| Cash and cash equivalents translation differences..... | 123 | 169 | 381 |
| (Decrease) increase in cash and cash equivalents..... | (12,541) | 2,661 | 7,749 |
| Cash and cash equivalents at the beginning of the period..... | 45,820 | 37,817 | 37,817 |
| Cash and cash equivalents of newly consolidated subsidiaries at the beginning of the period | 85 | 253 | 253 |
| Cash and cash equivalents at the end of the period | 33,364 | 40,732 | 45,820 |



4. Segment information

Fiscal 2006 Q3 Segment information by business type (April 1, 2006 – December 31, 2006)

| | <i>Millions of yen</i> | | | | | | | |
|---------------------------------------|------------------------|---------------|---------------|---------------|---------------|----------------|-----------------------|----------------|
| | Pharmaceuticals | Bio-Chemicals | Chemicals | Food | Other | Total | Elimination/Corporate | Consolidated |
| Net sales | | | | | | | | |
| (1) Sales to external customers | 100,453 | 41,969 | 68,742 | 29,545 | 27,402 | 268,113 | -- | 268,113 |
| (2) Inter-segment sales and transfers | 402 | 7,702 | 4,721 | 3,203 | 9,625 | 25,654 | (25,654) | -- |
| Total sales | 100,855 | 49,672 | 73,463 | 32,748 | 37,028 | 293,768 | (25,654) | 268,113 |
| Operating expenses | 84,267 | 46,904 | 68,425 | 31,107 | 36,271 | 266,976 | (25,736) | 241,240 |
| Operating income | 16,588 | 2,767 | 5,037 | 1,641 | 756 | 26,791 | 81 | 26,873 |

Fiscal 2005 Q3 Segment information by business type (April 1, 2005 – December 31, 2005)

| | <i>Millions of yen</i> | | | | | | | |
|---------------------------------------|------------------------|---------------|---------------|---------------|---------------|----------------|-----------------------|----------------|
| | Pharmaceuticals | Bio-Chemicals | Chemicals | Food | Other | Total | Elimination/Corporate | Consolidated |
| Net sales: | | | | | | | | |
| (1) Sales to external customers | 118,734 | 35,886 | 59,948 | 28,919 | 28,768 | 272,258 | -- | 272,258 |
| (2) Inter-segment sales and transfers | 263 | 6,777 | 4,026 | 3,525 | 12,317 | 26,910 | (26,910) | -- |
| Total sales | 118,998 | 42,663 | 63,974 | 32,445 | 41,085 | 299,168 | (26,910) | 272,258 |
| Operating expenses | 105,103 | 39,851 | 60,367 | 30,913 | 40,142 | 276,379 | (27,000) | 249,379 |
| Operating income | 13,894 | 2,812 | 3,606 | 1,531 | 943 | 22,788 | 89 | 22,878 |

Fiscal 2005 Segment information by business type (April 1, 2005 - March 31, 2006)

| | <i>Millions of yen</i> | | | | | | | |
|---------------------------------------|------------------------|---------------|---------------|---------------|---------------|----------------|-----------------------|----------------|
| | Pharmaceuticals | Bio-Chemicals | Chemicals | Food | Other | Total | Elimination/Corporate | Consolidated |
| Net sales: | | | | | | | | |
| (1) Sales to external customers | 149,146 | 48,346 | 80,231 | 37,929 | 37,785 | 353,439 | -- | 353,439 |
| (2) Inter-segment sales and transfers | 388 | 9,077 | 5,603 | 4,510 | 17,582 | 37,162 | (37,162) | -- |
| Total sales | 149,535 | 57,423 | 86,834 | 42,440 | 55,368 | 390,602 | (37,162) | 353,439 |
| Operating expenses | 135,305 | 53,340 | 81,334 | 40,838 | 54,212 | 365,031 | (37,125) | 327,905 |
| Operating income | 14,230 | 4,083 | 4,500 | 1,602 | 1,155 | 25,571 | (36) | 25,534 |



Segment information by location

April 1, 2006 – December 31, 2006

As Japan represents over 90% of the total sales of each segment, this information has been omitted.

April 1, 2005 – December 31, 2005

As quarterly segment information by location has only been presented from the first quarter of the fiscal year ending March 31, 2007, this date has been omitted.

April 1, 2005 – March 31, 2006

As Japan represents over 90% of the total sales of each segment, this information has been omitted.

Overseas Sales

April 1, 2006 – December 31, 2006

Millions of yen

| | America | Europe | Asia | Other Regions | Total |
|--|---------|--------|--------|---------------|---------|
| (1) Overseas sales | 15,441 | 12,048 | 20,446 | 348 | 48,285 |
| (2) Consolidated sales | | | | | 286,113 |
| (3) Overseas sales as a percentage of consolidated sales (%) | 5.8 | 4.5 | 7.6 | 0.1 | 18.0 |

April 1, 2005 – December 31, 2005

As quarterly segment information by overseas sales has only been presented from the first quarter of the fiscal year ending March 31, 2007, this date has been omitted.

April 1, 2005 – March 31, 2006

Millions of yen

| | America | Europe | Asia | Other Regions | Total |
|--|---------|--------|--------|---------------|---------|
| (1) Overseas sales | 15,138 | 13,608 | 25,548 | 643 | 54,938 |
| (2) Consolidated sales | | | | | 353,439 |
| (3) Overseas sales as a percentage of consolidated sales (%) | 4.3 | 3.9 | 7.2 | 0.2 | 15.5 |